17.04 -0.69 (-3.89%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 20.64 | 1-year : | 22.58 |
Resists | First : | 17.67 | Second : | 19.34 |
Pivot price | 16.49 | |||
Supports | First : | 14.97 | Second : | 12.46 |
MAs | MA(5) : | 17.01 | MA(20) : | 16.81 |
MA(100) : | 12.91 | MA(250) : | 11.3 | |
MACD | MACD : | 0 | Signal : | 0 |
%K %D | K(14,3) : | 72.6 | D(3) : | 60.7 |
RSI | RSI(14): 52.9 | |||
52-week | High : | 19.68 | Low : | 7.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CGEM ] has closed below upper band by 29.3%. Bollinger Bands are 16% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 17.82 - 17.91 | 17.91 - 17.98 |
Low: | 16.82 - 16.91 | 16.91 - 16.99 |
Close: | 16.9 - 17.05 | 17.05 - 17.17 |
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Fri, 29 Mar 2024
Citigroup Inc. Raises Stake in Cullinan Oncology, Inc. (NASDAQ:CGEM) - Defense World
Fri, 22 Mar 2024
Cullinan Oncology, Inc. (NASDAQ:CGEM) Holdings Lifted by Exchange Traded Concepts LLC - Defense World
Mon, 18 Mar 2024
Cullinan Oncology, Inc. (NASDAQ:CGEM) Forecasted to Earn Q2 2024 Earnings of ($0.98) Per Share - MarketBeat
Fri, 15 Mar 2024
Is Cullinan Oncology Inc (CGEM) a Winner in the Healthcare Sector? - InvestorsObserver
Fri, 15 Mar 2024
Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation - Yahoo Finance
Thu, 14 Mar 2024
Cullinan Oncology Inc reports results for the quarter ended in December - Earnings Summary - TradingView
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 43 (M) |
Shares Float | 26 (M) |
Held by Insiders | 7.1 (%) |
Held by Institutions | 94.6 (%) |
Shares Short | 694 (K) |
Shares Short P.Month | 1,470 (K) |
EPS | -3.7 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 10.57 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -22.8 % |
Return on Equity (ttm) | -31.4 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -4.42 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -134 (M) |
Levered Free Cash Flow | -89 (M) |
PE Ratio | -4.62 |
PEG Ratio | 0 |
Price to Book value | 1.61 |
Price to Sales | 0 |
Price to Cash Flow | -5.47 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |